Shares in Sareum Holdings PLC (AIM:SAR) jumped by 10% in early Monday trading after the drug developer announced the successful phase Ia dosing of its lead programme, SDC-1801.
The early-stage study, being conducted in Melbourne, Australia, involves subjects receiving the potential treatment for psoriasis orally for 10 days.
Researchers will assess the safety and effectiveness of an oral formulation of SDC-1801 in healthy participants.
Early results from the trial have been promising, suggesting a favourable profile for daily oral dosing.
Comprehensive safety data is anticipated by the first half of 2024. If results remain positive, a phase Ib study on psoriasis patients will follow shortly after.
At 9.24 am, the stock was changing hands for 85p, up 7.5p.